Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 17/20 | 0.85 |
| ▸ | TDO2 | P48775 | 16/20 | 0.85 |
| ▸ | IDO2 | Q6ZQW0 | 12/20 | 0.85 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | APAF1 | O14727 | 1/20 | 0.60 |
| ▸ | NPC1 | O15118 | 1/20 | 0.60 |
| ▸ | MITF | O75030 | 1/20 | 0.60 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.60 |
| ▸ | RAB9A | P51151 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | TRPV4 | Q9HBA0 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17830812 | 0.92 | TDO2 (1.00) | IDO1TDO2IDO2MEN1APAF1 | |
| SCHEMBL17830820 | 0.88 | TDO2 (0.69) | IDO1TDO2IDO2MEN1APAF1 | |
| SCHEMBL5618397 | 0.88 | IDO1 (0.66) | IDO1TDO2IDO2MEN1APAF1 | |
| SCHEMBL9101591 | 0.83 | IDO1 (0.63) | IDO1TDO2IDO2MEN1APAF1 | |
| SCHEMBL4585634 | 0.83 | IDO1 (0.80) | IDO1TDO2IDO2MEN1APAF1 | |
| SCHEMBL26614094 | 0.83 | IDO1 (0.85) | IDO1TDO2IDO2MEN1APAF1 | |
| SCHEMBL9103498 | 0.81 | TDO2 (0.58) | IDO1TDO2IDO2MEN1APAF1 | |
| SCHEMBL26614214 | 0.81 | IDO1 (0.73) | IDO1TDO2IDO2MEN1APAF1 | |
| SCHEMBL17830806 | 0.81 | TDO2 (0.81) | IDO1TDO2IDO2MEN1APAF1 | |
| SCHEMBL17830811 | 0.81 | TDO2 (1.00) | IDO1TDO2IDO2MEN1APAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120244182-A1 | USE OF TRYPTANTHRIN COMPOUNDS FOR IMMUNE POTENTIATION | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2012-09-27 | — | — | US | disclosed |
| US-20120244182-A1 | USE OF TRYPTANTHRIN COMPOUNDS FOR IMMUNE POTENTIATION | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2012-09-27 | — | — | US | disclosed |
| EP-1594524-B1 | USE OF TRYPTANTHRIN COMPOUNDS FOR IMMUNE POTENTIATION | NOVARTIS VACCINES & DIAGNOSTIC (US) | 2012-08-15 | — | — | EP | disclosed |
| EP-1594524-B1 | USE OF TRYPTANTHRIN COMPOUNDS FOR IMMUNE POTENTIATION | NOVARTIS VACCINES & DIAGNOSTIC (US) | 2012-08-15 | — | — | EP | disclosed |
| US-8193185-B2 | Administering a tryptanthrin compound, e.g., 8-nitroindolo[2,1-b]quinazoline-6,12-dione, to potentiate the immune response to an antigen; immunostimulants; small molecule immune potentiators; immunotherapy for infectious diseases; anticarcinogenic agents; vaccine adjuvant compositions and kits | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2012-06-05 | — | — | US | disclosed |
| US-8193185-B2 | Administering a tryptanthrin compound, e.g., 8-nitroindolo[2,1-b]quinazoline-6,12-dione, to potentiate the immune response to an antigen; immunostimulants; small molecule immune potentiators; immunotherapy for infectious diseases; anticarcinogenic agents; vaccine adjuvant compositions and kits | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2012-06-05 | — | — | US | disclosed |
| US-8193185-B2 | Administering a tryptanthrin compound, e.g., 8-nitroindolo[2,1-b]quinazoline-6,12-dione, to potentiate the immune response to an antigen; immunostimulants; small molecule immune potentiators; immunotherapy for infectious diseases; anticarcinogenic agents; vaccine adjuvant compositions and kits | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2012-06-05 | — | — | US | disclosed |
| US-8012987-B2 | Indolo[2,1-b] quinazole-6,12-dione antimalarial compounds and methods of treating malaria therewith | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE ARMY (US) | 2011-09-06 | — | — | US | disclosed |
| US-8012987-B2 | Indolo[2,1-b] quinazole-6,12-dione antimalarial compounds and methods of treating malaria therewith | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE ARMY (US) | 2011-09-06 | — | — | US | disclosed |
| EP-1032574-B1 | INDOLO 2,1-b|QUINAZOLE-6,12-DIONE ANTIMALARIAL COMPOUNDS AND METHODS OF TREATING MALARIA THEREWITH | US ARMY (US) | 2007-06-13 | — | — | EP | disclosed |
| US-5441955-A | Tuberculosis | PATHOGENESIS CORPORATION (US) | 1995-08-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120244182-A1 | USE OF TRYPTANTHRIN COMPOUNDS FOR IMMUNE POTENTIATION | TPSG1, TPSB2, TPSAB1 | IDO1 20/4885TDO2 66/4885IDO2 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.